Clinical Trials Browser

Interventional × Carcinoma × ensartinib × Clear all

NCT02898116 2022-10-10

Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer

Phase 1/2 Completed

2 enrolled 8 charts

Carcinoma, Carcinoma, Non-Small-Cell Lung